Sacyr SA (SCYR)
Madrid Stock Exchange · Spain · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 4.046 |
|---|---|
| 52-week range | 3.554 – 4.952 |
| Return, 1 month / 3 months | +0.1% / −14.4% |
| Return, 1 year / 3 years | +6.5% / +73.5% |
| Trend | Below its 200-day average |
| RSI (14) | 51 |
| Volatility (1 year) | 25.7% |
| Worst drawdown (1 year) | -21.2% |
| Average daily value traded | 10.34M EUR |
| Dividend yield | 3.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Sacyr is a Spanish construction and infrastructure group based in Madrid. It designs and builds civil engineering works such as roads, motorways, bridges and public facilities, and it operates many of these assets under long-term concession agreements with governments and public authorities. The company also provides water treatment and environmental services and carries out industrial and building projects for public and private customers, mainly in Spain and other countries.
On this site Sacyr SA appears as a stock on the Madrid Stock Exchange (Spain), code SCYR, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Sacyr SA (SCYR) trades on the Madrid Stock Exchange in Spain. It last closed at EUR 4.046 on 27 October 2026.
Its price-based Market X-Ray is 48 out of 100 (a weak price profile), ranking 137 of 236 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 6.5% and over the last three months it fell 14.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Madrid Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 33 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -6.9% | ||
| From 52-week high | -17.8% | ||
| Momentum | 36 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -14.4% | ||
| 6-month return | -11.0% | ||
| 12-month return, skipping the last month | 6.4% | ||
| Stability (higher is calmer) | 47 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 25.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -21.2% | ||
| Liquidity | 89 · Strong | Trades actively. | |
| Average daily value traded | 10.34M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 56 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 3.7% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +0.9% |
|---|---|
| 1 month | +0.1% |
| 3 months | −14.4% |
| 6 months | −11.0% |
| 1 year | +6.5% |
| 3 years | +73.5% |
| 5 years | +104.4% |
Signals
| 50-day / 200-day average | 4.118 / 4.348 |
|---|---|
| Golden / death cross (60 days) | Death, 17 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.087 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 29 Jun 2026 | EUR 0.1000 |
| 13 Jan 2026 | EUR 0.0490 |
| 27 Jun 2025 | EUR 0.0450 |
| 14 Jan 2025 | EUR 0.0780 |
| 10 Sep 2024 | EUR 0.0790 |
| 12 Jan 2024 | EUR 0.0620 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Madrid Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.